Chat with Impileo

ptr-pts-calculation

ACEIM-MR Tablets : Top-Quality Aceclofenac, Paracetamol, and Chlorzoxazone Formulation by Trusted Third-Party Manufacturing in Panchkula



ACEIM-MR Tablets (Aceclofenac + Paracetamol + Chlorzoxazone)

Indication :

  • ACEIM-MR tablets provide effective relief from pain and inflammation associated with various musculoskeletal and inflammatory conditions, offering comprehensive management for discomfort.

 ACEIM-MR Tablets : Top-Quality Aceclofenac, Paracetamol, and Chlorzoxazone Formulation by Trusted Third-Party Manufacturing in Panchkula

Composition :

Each tablet of ACEIM-MR contains:

  • Aceclofenac   100mg
  • Paracetamol   325mg 
  • Chlorzoxazone  250mg

Uses Of ACEIM-MR Tablet :

  • Musculoskeletal pain
  • Rheumatoid arthritis
  • Osteoarthritis
  • Ankylosing spondylitis
  • Acute back pain
  • Dental pain
  • Postoperative pain

Side Effects Of ACEIM-MR Tablet :

  • Nausea
  • Gastric irritation or ulceration
  • Dizziness
  • Drowsiness
  • Skin rash or itching

Packaging Of ACEIM-MR Tablet : 

  • ALU-ALU   10X10

Dosage Of ACEIM-MR Tablet : 

  • The dosage of ACEIM-MR should be individualized based on the patient's condition, response to treatment, and any pre-existing medical conditions.
  • It is essential to follow the prescribed dosage and schedule as directed by the healthcare provider.

Disclaimer :

  • Impileo Lifescience Private Limited, a trusted name in the PCD Pharma franchise sector, presents this content to inform individuals exploring PCD Pharma franchise opportunities. However, it's important to note that this information is not a substitute for medical advice.

 

“Step into a realm of excellence with Impileo Lifescience, where premium pharmaceuticals and unwavering quality converge. As a leading Third-Party Manufacturing company in Panchkula, we are celebrated for our reliability and applauded for our meteoric rise.”

 

Impileo Lifescience Pvt Ltd

Click here To Contact on WhatsApp

Phone: +91 9041633399

Email: impileolifescience@gmail.com

Comments are closed